Given the lack of influence of TBC and E2 on the inhibition of the proliferation of the ERα-negative human breast cancer line MDA-MB-231, it was concluded that the mechanism of the antiestrogenic action of TBC involves the ERα pathway [22]. Here, ESR1 is linked to breast carcinoma.